Composition for activating neurogenesis

Patent metadata

Field	Value
Publication number	US-11318126-B2
Application number	US-201716329063-A
Country	US
Kind code	B2
Filing date	Aug 31, 2017
Priority date	Aug 31, 2016
Publication date	May 3, 2022
Grant date	May 3, 2022

Abstract

Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition. A composition for activating neurogenesis contains, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing, improving, inhibiting the development of, and/or treating a disease of the central nervous system and/or the peripheral nervous system, or for improving, inhibiting the development of, and/or treating a functional disorder of the central nervous system and/or the peripheral nervous system, the composition containing, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

First claim

The invention claimed is:

1. A method for:
treating a disease of the central nervous system and/or the peripheral nervous system, or
treating a functional disorder of the central nervous system and/or the peripheral nervous system,
wherein the method comprises administering, to a subject, a composition comprising, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof,
the compound is

the disease of the central nervous system and/or the peripheral nervous system is Down syndrome, Alzheimer's disease or facial palsy, and
the functional disorder of the central nervous system and/or the peripheral nervous system is a spinal cord injury.

2. The method according to claim 1 , wherein the compound activates neurogenesis.

3. The method according to claim 1 , wherein the protein kinase is at least one of DYRK and a cyclin D1 kinase.

Assignees

• Univ Kyoto

Inventors

• Hagiwara Masatoshi
• Kobayashi Akiko
• Hosoya Takamitsu
• Yoshida Suguru
• SUMIDA Yuto

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/47 Primary

  Quinolines; Isoquinolines · CPC title

• A61K31/416

  condensed with carbocyclic ring systems, e.g. indazole · CPC title